Nina Tandon

She grows customer human bones in a lab.

Bone graft surgeries are brutal.

They require two operations: one to harvest the bone, another to implant it.

Infection, rejection, and long recovery times are the norm.

Nina Tandon is changing that.

She’s the CEO and co-founder of EpiBone, the first company to grow living human bones from a patient’s own stem cells.

Customized to fit perfectly and continue growing with the body.

In 2023, EpiBone became the first company approved by the FDA to begin testing lab-grown bones in humans.

A second product is already in clinical trials.

In just three weeks, her team can grow a bone that’s surgery-ready.

So how did Nina get here?

She studied electrical engineering.

Built cancer-sniffing devices in Rome.

Grew beating heart tissue at Columbia.

Earned a PhD in cardiac tissue engineering and an MBA to bring her lab work into the real world.

Her mission: to make the body a renewable resource. “We don't just heal the body,” she says. “We build it.”

EpiBone’s breakthrough tech (bioreactors that mimic the human body) has attracted $42M in funding and global recognition, from TED to the World Economic Forum.

She’s been featured in Forbes, Netflix’s Human: The World Within, and even spoke at the White House on biotech policy.